Cited 67 times in
Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강영애 | - |
dc.date.accessioned | 2014-12-18T09:21:46Z | - |
dc.date.available | 2014-12-18T09:21:46Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1073-449X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88030 | - |
dc.description.abstract | RATIONALE: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. OBJECTIVES: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. METHODS: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions. MEASUREMENTS AND MAIN RESULTS: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27-2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75). CONCLUSIONS: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with www.clinicaltrials.gov (NCT 01055145). | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antitubercular Agents/administration & dosage | - |
dc.subject.MESH | Antitubercular Agents/pharmacology | - |
dc.subject.MESH | Antitubercular Agents/therapeutic use | - |
dc.subject.MESH | Aza Compounds/administration & dosage | - |
dc.subject.MESH | Aza Compounds/pharmacology | - |
dc.subject.MESH | Aza Compounds/therapeutic use* | - |
dc.subject.MESH | Fluoroquinolones | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Levofloxacin/administration & dosage | - |
dc.subject.MESH | Levofloxacin/pharmacology | - |
dc.subject.MESH | Levofloxacin/therapeutic use* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quinolines/administration & dosage | - |
dc.subject.MESH | Quinolines/pharmacology | - |
dc.subject.MESH | Quinolines/therapeutic use* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Sputum/drug effects | - |
dc.subject.MESH | Sputum/microbiology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tuberculosis, Multidrug-Resistant/drug therapy* | - |
dc.subject.MESH | Tuberculosis, Pulmonary/drug therapy* | - |
dc.subject.MESH | Young Adult | - |
dc.title | Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Won-Jung Koh | - |
dc.contributor.googleauthor | Seung Heon Lee | - |
dc.contributor.googleauthor | Young Ae Kang | - |
dc.contributor.googleauthor | Chang-Hoon Lee | - |
dc.contributor.googleauthor | Jae Chol Choi | - |
dc.contributor.googleauthor | Jae Ho Lee | - |
dc.contributor.googleauthor | Seung Hun Jang | - |
dc.contributor.googleauthor | Kwang Ha Yoo | - |
dc.contributor.googleauthor | Ki Hwan Jung | - |
dc.contributor.googleauthor | Ki Uk Kim | - |
dc.contributor.googleauthor | Sang Bong Choi | - |
dc.contributor.googleauthor | Yon Ju Ryu | - |
dc.contributor.googleauthor | Kyung Chan Kim | - |
dc.contributor.googleauthor | Soojung Um | - |
dc.contributor.googleauthor | Yong Soo Kwon | - |
dc.contributor.googleauthor | Yee Hyung Kim | - |
dc.contributor.googleauthor | Won-Il Choi | - |
dc.contributor.googleauthor | Kyeongman Jeon | - |
dc.contributor.googleauthor | Yong Il Hwang | - |
dc.contributor.googleauthor | Se Joong Kim | - |
dc.contributor.googleauthor | Young Seok Lee | - |
dc.contributor.googleauthor | Eun Young Heo | - |
dc.contributor.googleauthor | Juhee Lee | - |
dc.contributor.googleauthor | Yeo Woon Ki | - |
dc.contributor.googleauthor | Tae Sun Shim | - |
dc.contributor.googleauthor | Jae-Joon Yim | - |
dc.identifier.doi | 10.1164/rccm.201303-0604OC | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00057 | - |
dc.relation.journalcode | J00112 | - |
dc.identifier.eissn | 1535-4970 | - |
dc.identifier.pmid | 23927582 | - |
dc.identifier.url | http://www.atsjournals.org/doi/abs/10.1164/rccm.201303-0604OC?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed | - |
dc.subject.keyword | multidrug-resistant tuberculosis | - |
dc.subject.keyword | fluoroquinolone | - |
dc.subject.keyword | moxifloxacin | - |
dc.subject.keyword | levofloxacin | - |
dc.contributor.alternativeName | Kang, Young Ae | - |
dc.contributor.affiliatedAuthor | Kang, Young Ae | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 188 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 858 | - |
dc.citation.endPage | 864 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol.188(7) : 858-864, 2013 | - |
dc.identifier.rimsid | 32713 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.